BioCentury | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

Acceleron is readying to send its pulmonary arterial hypertension candidate to Phase III after announcing late Monday that the therapy combined with standard of care met primary and secondary endpoints in a proof-of-concept Phase II...
BioCentury | Jan 15, 2020
Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

Denali reported data Tuesday from pair of Phase I trials that will inform the company’s selection of a Parkinson’s disease candidate to advance to Phase II. Denali Therapeutics Inc. (NASDAQ:DNLI) gained $5.16 (29%) to $22.74...
BioCentury | Dec 19, 2019

Skin grafts based on CRISPR-edited iPS cells to treat epidermolysis bullosa

DISEASE CATEGORY: Dermatology INDICATION: Blistering disorder Skin grafts based on CRISPR-edited induced pluripotent stem (iPS) cells could treat recessive dystrophic epidermolysis bullosa, a blistering disorder caused by mutations in COL7A1. Generation of the full-thickness grafts...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jun 4, 2019
Distillery Therapeutics

BMP2- and lysostaphin-loaded hydrogel for bone repair, infection

...CATEGORY: Infectious disease; musculoskeletal INDICATION: Staphylococcus; bone repair Mouse studies suggest PEG-based hydrogel loaded with BMP2...
...animal models. TARGET/MARKER/PATHWAY: Bone morphogenetic protein 2 (BMP2); peptidoglycans in the cell wall of Staphyloccus aureus ; bone morphogenetic protein 2 (BMP2...
...Mechanical Engineering, Georgia Institute of Technology, Atlanta, Ga. email: andres.garcia@me.gatech.edu Sandi Wong Emory University Georgia Institute of Technology Bone morphogenetic protein 2 (BMP2) Bone...
BioCentury | Apr 30, 2019
Distillery Therapeutics

BMP2/BMP6/activin A-based chimera for bone repair

...BMP2, BMP6 and activin A sequences that could help repair bone.The chimera consists of human BMP2...
...the pro-healing effects of endogenously produced BMP2, in preclinical testing for bone repair. TARGET/MARKER/PATHWAY: Bone morphogenetic protein 2 (BMP2...
...2019 doi:10.1126/scitranslmed.aar4953 CONTACT: Howard J. Seeherman, Bioventus Inc., Durham, N.C. email: hseeherman@gmail.com Claire Quang Bioventus Inc. Activin A Bone morphogenetic protein 2 (BMP2) Bone...
BioCentury | Feb 6, 2019
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
BioCentury | Dec 21, 2018
Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) on Dec. 18 in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing...
BioCentury | Dec 18, 2018
Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing to begin "formal"...
BioCentury | Nov 13, 2018
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse studies suggest inhibiting BMP6 or promoting NOG expression could help treat cognitive dysfunction in AD. In a mouse model of AD, levels of BMP6 in the hippocampal dentate gyrus were...
Items per page:
1 - 10 of 176